Full Length Article| Volume 188, P31-38, April 2020

Prostaglandin E1 effects on CD62p and PAC-1 in patients with sudden sensorineural hearing loss

  • Jie Xi
    Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710068, Shaanxi, China
    Search for articles by this author
  • Hui Liu
    Corresponding author at: Shaanxi Provincial People's Hospital, 256 Youyi Western Road, Xi'an 710068, Shaanxi, China.
    Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital, Medical Research School of Northwestern Polytechnical University, 710068, Shaanxi, China
    Search for articles by this author
  • Xin Wang
    Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi, China
    Search for articles by this author


      • SSNHL patients have higher CD62p or PAC-1 positive platelets than healthy subjects.
      • Additional PGE1 treatment leads to more hearing gain than regular treatment.
      • PGE1 further reduces excessive platelet activation in SSNHL patients.
      • Higher initial CD62p and PAC-1 predict better clinical efficacy of PGE1 treatment.



      To evaluate the treatment outcome of vasodilator prostaglandin E1 (PGE1) in treating sudden sensorineural hearing loss (SSNHL) and to determine its effects on platelet activation, as reflected by changes in CD62p and PAC-1.


      We prospectively enrolled 60 patients with confirmed SSNHL and randomly divided them into two groups: the SSNHL group received regular therapy, and the SSNHL-PGE1 group received additional intravenous injection of PGE1. After 14 days of treatment, we measured clinical improvement and CD62p-positive and PAC-1-positive platelets. 30 healthy medical staff members were included as a control group.


      The SSNHL patients had significantly higher levels of CD62p-positive or PAC-1 positive platelets than the healthy subjects. The ratios of CD62p positive or PAC-1 positive platelets significantly decreased after the two treatments. The average pure tone (PTA) hearing thresholds decreased to 26.51 ± 12.65 dB in SSNHL-PGE1 group after treatment, which was significantly lower than that of the SSNHL group (34.46 ± 10.35 dB). Patients with initial severe or profound hearing loss (PTA ≥ 71 dB) had better hearing improvement on PGE1 than on the regular treatment. Patients in the SSNHL-PGE1 treatment group had significantly lower CD62p and PAC-1 levels than those in the SSNHL group. Patients with higher initial positive CD62p and PAC-1 ratios tended to have higher potential of clinical improvement and hearing gains after PGE1 treatment. Initial CD62p and PAC-1 levels were significantly correlated with hearing thresholds in patients with SSNHL.


      PGE1 application could improve treatment efficacy and suppress excessive platelet activation in patients with SSNHL.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jung S.Y.
        • Shim H.S.
        • Hah Y.M.
        • Kim S.H.
        • Yeo S.G.
        Association of metabolic syndrome with sudden sensorineural hearing loss.
        JAMA Otolaryngol. Head Neck Surg. 2018; 144: 308-314
        • Agarwal L.
        • Pothier D.D.
        Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss.
        Cochrane Database Syst. Rev. 2009; 4CD003422
        • Lee H.Y.
        • Kim D.K.
        • Park Y.H.
        • Cha W.W.
        • Kim G.J.
        • Lee S.H.
        Prognostic factors for profound sudden idiopathic sensorineural hearing loss: a multicenter retrospective study.
        Eur. Arch. Otorhinolaryngol. 2017; 274: 143-149
        • Sharaf K.
        • Ihler F.
        • Bertlich M.
        • Reichel C.A.
        • Berghaus A.
        • Canis M.
        Tumor necrosis factor-induced decrease of cochlear blood flow can be reversed by etanercept or JTE-013.
        Otol. Neurotol. 2016; 37: e203-e208
        • Tripodi A.
        • Capaccio P.
        • Pignataro L.
        • Chantarangkul V.
        • Menegatti M.
        • Bamonti F.
        • Clerici M.
        • De Giuseppe R.
        • Peyvandi F.
        Thrombin generation in patients with idiopathic sudden sensorineural hearing loss.
        Thromb. Res. 2014; 133: 1130-1134
        • Passamonti S.M.
        • Di Berardino F.
        • Bucciarelli P.
        • Berto V.
        • Artoni A.
        • Gianniello F.
        • Ambrosetti U.
        • Cesarani A.
        • Pappalardo E.
        • Martinelli I.
        Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome.
        Thromb. Res. 2015; 135: 508-512
        • Durmus K.
        • Terzi H.
        • Karatas T.D.
        • Dogan M.
        • Uysal I.O.
        • Sencan M.
        • Altuntas E.E.
        Assessment of hematological factors involved in development and prognosis of idiopathic sudden sensorineural hearing loss.
        J. Craniofac. Surg. 2016; 27: e85-e91
        • Mirvakili A.
        • Dadgarnia M.H.
        • Baradaranfar M.H.
        • Atighechi S.
        • Zand V.
        • Ansari A.
        Role of platelet parameters on sudden sensorineural hearing loss: a case-control study in Iran.
        PLoS One. 2016; 11e0148149
        • Sun Y.
        • Guo Y.
        • Wang H.
        • Chen Z.
        • Wu Y.
        • Shi H.
        • Feng Y.
        • Yin S.
        Differences in platelet-related parameters among patients with audiographically distinct sudden sensorineural hearing loss: a retrospective study.
        Medicine (Baltimore). 2017; 96e7877
        • Ulu S.
        • Ulu M.S.
        • Ahsen A.
        • Yucedag F.
        • Aycicek A.
        • Celik S.
        Increased levels of mean platelet volume: a possible relationship with idiopathic sudden hearing loss.
        Eur. Arch. Otorhinolaryngol. 2013; 270: 2875-2878
        • Estevez B.
        • Du X.
        New concepts and mechanisms of platelet activation signaling.
        Physiology (Bethesda). 2017; 32: 162-177
        • Tong S.
        • Wang H.
        • Zhang T.
        • Chen L.
        • Liu B.
        Accumulation of CD62P during storage of apheresis platelet concentrates and the role of CD62P in transfusion-related acute lung injury.
        Mol. Med. Rep. 2015; 12: 7777-7781
        • Fox S.C.
        • May J.A.
        • Dovlatova N.
        • Glenn J.R.
        • Johnson A.
        • White A.E.
        • Radhakrishnan A.
        • Heptinstall S.
        How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy?.
        Platelets. 2019; 30: 290-295
        • Lee H.J.
        • Park C.Y.
        • Lee J.H.
        • Yang H.S.
        • Kim J.H.
        • Ban M.J.
        • Moon I.S.
        Therapeutic effects of carbogen inhalation and lipo-prostaglandin E1 in sudden hearing loss.
        Yonsei Med. J. 2012; 53: 999-1004
        • Zhuo X.L.
        • Wang Y.
        • Zhuo W.L.
        • Zhang X.Y.
        Is the application of prostaglandin E1 effective for the treatment of sudden hearing loss? An evidence-based meta-analysis.
        J. Int. Med. Res. 2008; 36: 467-470
        • Lee H.Y.
        • Kim J.C.
        • Choi M.S.
        • Chang D.S.
        • Kim A.Y.
        • Cho C.S.
        Therapeutic effect of combined steroid-lipoprostaglandin E1 for sudden hearing loss: a propensity score-matched analysis.
        Am. J. Otolaryngol. 2015; 36: 52-56
        • Chinese Journal of Otolaryngology, Chinese Academy of Otolaryngology Head and Neck Surgery
        Guideline of diagnosis and treatment of sudden deafness (2005, Jinan).
        Chin. J. Otorhinolaryngol. Head Neck Surg. 2006; 41: 569
        • Stachler R.J.
        • Chandrasekhar S.S.
        • Archer S.M.
        • Rosenfeld R.M.
        • Schwartz S.R.
        • Barrs D.M.
        • Brown S.R.
        • Fife T.D.
        • Ford P.
        • Ganiats T.G.
        Clinical practice guideline: sudden hearing loss.
        Otolaryngology Head Neck Surg. 2012; 146: S1-35
        • Ashtiani M.K.
        • Firouzi F.
        • Bastaninejad S.
        • Dabiri S.
        • Nasirmohtaram S.
        • Saeedi N.
        • Ghazavi H.
        • Sahebi L.
        Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial.
        Eur. Arch. Otorhinolaryngol. 2018; 275: 89-97
        • Michelson A.D.
        Evaluation of platelet function by flow cytometry.
        Pathophysiol. Haemost. Thromb. 2006; 35: 67-82
        • Plontke S.K.
        Diagnostics and therapy of sudden hearing loss.
        GMS Curr Top Otorhinolaryngol Head Neck Surg. 2018; 16 (Doc05)
        • Demirhan H.
        • Gokduman A.R.
        • Hamit B.
        • Altindag M.F. Yurekli
        • Yigit O.
        Contribution of intratympanic steroids in the primary treatment of sudden hearing loss.
        Acta Otolaryngol. 2018; : 1-4
        • Conlin A.E.
        • Parnes L.S.
        Treatment of sudden sensorineural hearing loss: II. A meta-analysis.
        Arch. Otolaryngol. Head Neck Surg. 2007; 133: 582-586
        • Salvago P.
        • Rizzo S.
        • Bianco A.
        • Martines F.
        Sudden sensorineural hearing loss: is there a relationship between routine haematological parameters and audiogram shapes?.
        Int. J. Audiol. 2017; 56: 148-153
        • Lawall H.
        • Pokrovsky A.
        • Checinski P.
        • Ratushnyuk A.
        • Hamm G.
        • Randerath O.
        • Grieger F.
        • Bentz J.W.G.
        Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease fontaine stage IV: results of a placebo controlled randomised multicentre trial (ESPECIAL).
        Eur. J. Vasc. Endovasc. Surg. 2017; 53: 559-566
        • Geng N.
        • Zou D.
        • Chen Y.
        • Ren L.
        • Xu L.
        • Pang W.
        • Sun Y.
        Prostaglandin E1 administration for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials.
        Medicine (Baltimore). 2018; 97e11416
        • Gezginci-Oktayoglu S.
        • Orhan N.
        • Bolkent S.
        Prostaglandin-E1 has a protective effect on renal ischemia/reperfusion-induced oxidative stress and inflammation mediated gastric damage in rats.
        Int. Immunopharmacol. 2016; 36: 142-150
        • Suzuki H.
        • Fujimura T.
        • Ikeda K.
        • Shiomori T.
        • Udaka T.
        • Ohbuchi T.
        • Nagatani G.
        Prostaglandin E1 in combination with hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss.
        Acta Otolaryngol. 2008; 128: 61-65
        • Shim H.S.
        • Kim J.S.
        • Kim M.G.
        Comparative analysis of the combined therapeutic effects of lipoprostaglandin E1 on sudden idiopathic sensorineural hearing loss.
        J. Audiol. Otol. 2017; 21: 33-38
        • Moon I.S.
        • Kim J.
        • Lee S.Y.
        • Choi H.S.
        • Lee W.S.
        How long should the sudden hearing loss patients be followed after early steroid combination therapy?.
        Eur. Arch. Otorhinolaryngol. 2009; 266: 1391-1395
        • Yau J.W.
        • Teoh H.
        • Verma S.
        Endothelial cell control of thrombosis.
        BMC. Cardiovasc. Disord. 2015; 15: 130
        • Yun S.H.
        • Sim E.H.
        • Goh R.Y.
        • Park J.I.
        • Han J.Y.
        Platelet activation: the mechanisms and potential biomarkers.
        Biomed. Res. Int. 2016; 20169060143
        • Secor D.
        • Swarbreck S.
        • Ellis C.G.
        • Sharpe M.D.
        • Feng Q.
        • Tyml K.
        Ascorbate inhibits platelet-endothelial adhesion in an in-vitro model of sepsis via reduced endothelial surface P-selectin expression.
        Blood Coagul. Fibrinolysis. 2017; 28: 28-33
        • Ciccone M.M.
        • Cortese F.
        • Pinto M.
        • Di Teo C.
        • Fornarelli F.
        • Gesualdo M.
        • Mezzina A.
        • Sabatelli E.
        • Scicchitano P.
        • Quaranta N.
        Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss.
        Atherosclerosis. 2012; 225: 511-516
        • Quaranta N.
        • De Ceglie V.
        • D'Elia A.
        Endothelial dysfunction in idiopathic sudden sensorineural hearing loss: a review.
        Audiol Res. 2016; 6: 151
        • Rondina M.T.
        • Grissom C.K.
        • Men S.
        • Harris E.S.
        • Schwertz H.
        • Zimmerman G.A.
        • Weyrich A.S.
        Whole blood flow cytometry measurements of in vivo platelet activation in critically-ill patients are influenced by variability in blood sampling techniques.
        Thromb. Res. 2012; 129: 729-735
        • Lee S.Y.
        • Kang M.J.
        • Cha J.K.
        Cilostazol reduces PAC-1 expression on platelets in ischemic stroke.
        J. Clin. Neurol. 2008; 4: 148-152
        • Pretorius L.
        • Thomson G.J.A.
        • Adams R.C.M.
        • Nell T.A.
        • Laubscher W.A.
        • Pretorius E.
        Platelet activity and hypercoagulation in type 2 diabetes.
        Cardiovasc. Diabetol. 2018; 17: 141
        • Yoon S.H.
        • Kim M.E.
        • Kim H.Y.
        • Lee J.S.
        • Jang C.H.
        Inflammatory cytokines and mononuclear cells in sudden sensorineural hearing loss.
        J. Laryngol. Otol. 2019; 133: 95-101
        • Iyu D.
        • Juttner M.
        • Glenn J.R.
        • White A.E.
        • Johnson A.J.
        • Fox S.C.
        • Heptinstall S.
        PGE1 and PGE2 modify platelet function through different prostanoid receptors.
        Prostaglandins Other Lipid Mediat. 2011; 94: 9-16
        • Kreutz R.P.
        • Nystrom P.
        • Kreutz Y.
        • Miao J.
        • Kovacs R.
        • Desta Z.
        • Flockhart D.A.
        • Jin Y.
        Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
        Platelets. 2013; 24: 145-150
        • Zhang Y.
        • Guan D.L.
        • Xia C.Q.
        • Han Z.Y.
        • Xu J.J.
        • Gao J.Z.
        • Wu K.R.
        Clinical study of lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation.
        Transplant Proc. 2005; 37: 4208-4210